Dr. Bleakman is an advisor to Acelot. He is an internationally recognized neuroscientist and expert in drug discovery with extensive experience working with renowned biotechnology companies. Dr. Bleakman is currently the President of Drug Discovery and Development at PsychoGenics, a preclinical CRO finding solutions to severely debilitating CNS disorders. Prior to this position, he served in a variety of leadership roles over the course of 25 years, including leadership positions at Eli Lilly and Company, where he served as Vice President and Chief Scientific Officer. He was responsible for creating strategies and leading research programs and teams to advance drug discovery for pain, migraine, and psychiatric disorders, leading molecules from target identification to clinical proof of concept. He was also the Chief Scientific Officer at Redpin Therapeutics, Inc. Dr. Bleakman is also an Adjunct Professor in the Department of Neuroscience at the Icahn School of Medicine at Mount Sinai.

Dr. Bleakman earned a PhD in General Physiology from King’s College London and completed a post-doctoral fellowship at the University of Chicago.